MA27684A1 - Preparation et utilisation de derives d'imidazole dans le traitement de l'obesite - Google Patents
Preparation et utilisation de derives d'imidazole dans le traitement de l'obesiteInfo
- Publication number
- MA27684A1 MA27684A1 MA27653A MA27653A MA27684A1 MA 27684 A1 MA27684 A1 MA 27684A1 MA 27653 A MA27653 A MA 27653A MA 27653 A MA27653 A MA 27653A MA 27684 A1 MA27684 A1 MA 27684A1
- Authority
- MA
- Morocco
- Prior art keywords
- obesity
- imidazole derivatives
- preparation
- treatment
- weight loss
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des dérivés imidazoles substitués dont il a été avéré qu'ils suppriment l'appétit et induisent une perte de poids. L'invention fournit également des méthodes de synthèse des composés, des compositions pharmaceutiques comprenant les composés, et des méthodes d'utilisation de ces compositions en vue d'induire une perte de poids et traiter l'obésité et les troubles liés à l'obésité.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32447301P | 2001-09-24 | 2001-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27684A1 true MA27684A1 (fr) | 2006-01-02 |
Family
ID=23263739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27653A MA27684A1 (fr) | 2001-09-24 | 2004-04-23 | Preparation et utilisation de derives d'imidazole dans le traitement de l'obesite |
Country Status (25)
Country | Link |
---|---|
US (2) | US6960601B2 (fr) |
EP (1) | EP1432691A1 (fr) |
JP (1) | JP2005508384A (fr) |
KR (1) | KR20040040472A (fr) |
CN (2) | CN1599724A (fr) |
AR (1) | AR036608A1 (fr) |
BR (1) | BR0212986A (fr) |
CA (1) | CA2459745A1 (fr) |
CO (1) | CO5560560A2 (fr) |
EC (1) | ECSP045076A (fr) |
GT (1) | GT200200188A (fr) |
HN (1) | HN2002000266A (fr) |
HR (1) | HRP20040308A2 (fr) |
HU (1) | HUP0402376A2 (fr) |
IL (1) | IL160524A0 (fr) |
MA (1) | MA27684A1 (fr) |
MX (1) | MXPA04002037A (fr) |
NO (1) | NO20041216L (fr) |
NZ (1) | NZ531841A (fr) |
PE (1) | PE20030547A1 (fr) |
PL (1) | PL369326A1 (fr) |
RU (1) | RU2004112770A (fr) |
UY (1) | UY27450A1 (fr) |
WO (1) | WO2003040107A1 (fr) |
ZA (1) | ZA200403035B (fr) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003007887A2 (fr) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
US7109216B2 (en) | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
EP1496838B1 (fr) | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Amides substitues |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
AU2003299791A1 (en) * | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
CN101012193A (zh) | 2003-01-02 | 2007-08-08 | 霍夫曼-拉罗奇有限公司 | 新cb 1受体反激动剂 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
KR20060005378A (ko) * | 2003-04-21 | 2006-01-17 | 다이이찌 세이야꾸 가부시기가이샤 | 5원 복소환 유도체 |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
AU2004261250B2 (en) | 2003-07-29 | 2009-02-26 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
US7662821B2 (en) | 2003-10-08 | 2010-02-16 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US7638515B2 (en) | 2003-10-08 | 2009-12-29 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
WO2005034939A1 (fr) | 2003-10-08 | 2005-04-21 | Schering Aktiengesellschaft | Derives de tetrahydronaphtalene a substitution 1-amino-2-oxy, procedes pour leur production et leur utilisation en tant qu'anti-inflammatoires |
CA2543338A1 (fr) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Nouvelles utilisations medicales de composes a activite antagoniste de cb1 et traitement combine impliquant ces composes |
EP1682535A1 (fr) | 2003-11-05 | 2006-07-26 | F. Hoffmann-La Roche Ag | Derives d'heteroaryle en tant qu'activateurs de ppar |
WO2005049593A2 (fr) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | Promoteurs de l'apoptose contenant n-acylsulfonamide |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
AU2005211451B2 (en) | 2004-01-28 | 2010-04-29 | F. Hoffmann-La Roche Ag | Spiro-benzodioxoles and their use as CB1 antagonists |
US7173044B2 (en) * | 2004-02-19 | 2007-02-06 | Solvay Pharmaceuticals B.V. | Imidazoline derivatives having CB1-antagonistic activity |
BRPI0508594A (pt) * | 2004-03-08 | 2007-08-21 | Wyeth Corp | moduladores de canal de ìon |
EP1723119A4 (fr) * | 2004-03-08 | 2009-11-25 | Wyeth Corp | Modulateurs de canal ionique |
AU2005221689A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
EP1734963A4 (fr) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques |
JP4177435B2 (ja) * | 2004-04-03 | 2008-11-05 | アストラゼネカ アクチボラグ | 治療薬 |
US20080153859A1 (en) | 2004-04-05 | 2008-06-26 | Hartmut Rehwinkel | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
BRPI0510679A (pt) | 2004-05-10 | 2007-12-26 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos |
US7524867B2 (en) * | 2004-05-28 | 2009-04-28 | Solvay Pharmaceuticals, B.V. | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
TW200616969A (en) * | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
RU2007119315A (ru) | 2004-10-25 | 2008-11-27 | Зольвай Фармасьютиклз Гмбх (De) | Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний |
JP4675969B2 (ja) | 2004-11-09 | 2011-04-27 | エフ.ホフマン−ラ ロシュ アーゲー | ジベンゾスベロン誘導体 |
WO2006060190A2 (fr) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Derives d'imidazole |
WO2006060199A2 (fr) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Derives d'imidazole utilises dans le traitement des dysfonctionnements sexuels |
AU2006203845A1 (en) * | 2005-01-10 | 2006-07-13 | Alexandros Makriyannis | Novel heteropyrrole analogs acting on cannabiniod receptors |
EP1843763A2 (fr) * | 2005-02-03 | 2007-10-17 | Irm, Llc | Composes et compositions utilises comme modulateurs de ppar |
WO2006088798A2 (fr) * | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Modulation de canaux potassiques sensibles a atp hypothalamiques |
US8937184B2 (en) | 2005-02-16 | 2015-01-20 | Abbvie B.V. | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators |
DE102005017316A1 (de) * | 2005-04-14 | 2006-10-19 | Schering Ag | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
PT1888550E (pt) | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
KR101363278B1 (ko) | 2005-06-27 | 2014-02-21 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | 이미다졸계 lxr 변조제 |
AT502258B1 (de) * | 2005-07-22 | 2007-09-15 | Univ Wien | Cox-i-inhibitorverbindungen |
EP1945635B1 (fr) * | 2005-08-18 | 2009-05-06 | F.Hoffmann-La Roche Ag | Derives de thiazolyle piperidine utile comme modulateurs du recepteur h3 |
GB0518819D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
GB0518817D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
WO2007037513A1 (fr) * | 2005-09-30 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | Composé hétérocyclique azoté substitué par un groupe aryle |
CA2630269C (fr) | 2005-11-28 | 2011-07-05 | F. Hoffmann-La Roche Ag | Inhibiteurs de diacylglycerol acyltransferase (dgat) |
EP1834948A1 (fr) | 2006-03-15 | 2007-09-19 | Bayer Schering Pharma Aktiengesellschaft | Derives de tetrahydronaphtalene , procedes pour leur production et leur utilisation en tant qu'anti-inflammatoires |
CA2649403C (fr) * | 2006-04-14 | 2011-06-21 | Merck & Co., Inc. | Imidazole 4-carboxamides substitues comme modulateurs des recepteurs de cholecystokinine 1 |
EP2010179B1 (fr) * | 2006-04-14 | 2010-07-07 | Merck Sharp & Dohme Corp. | 4-carboxamides d'imidazoles substitués utilisés comme modulateurs des récepteurs de la cholécystokinine-1 |
ATE479435T1 (de) * | 2006-04-14 | 2010-09-15 | Merck Sharp & Dohme | Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
ATE528006T1 (de) | 2007-01-26 | 2011-10-15 | Merck Sharp & Dohme | Substituierte aminopyrimidine als cholecystokinin-1-rezeptormodulatoren |
DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
GB2451629A (en) * | 2007-08-06 | 2009-02-11 | Univ Sheffield | 1-(Azolylcarbonyl)-2-(hydroxymethyl)pyrrolidine derivatives for use as catalysts for asymmetric reduction of imines & reductive amination of ketones |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
KR20170128623A (ko) | 2008-06-16 | 2017-11-22 | 유니버시티 오브 테네시 리서치 파운데이션 | 암 치료용 화합물 |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
CA2743489A1 (fr) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Amines bicycliques substituees pour le traitement du diabete |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
SI2376480T1 (sl) * | 2008-12-05 | 2016-10-28 | Abbvie Inc. | Sulfonamidni derivati kot Bcl-2-selektivna apoptozo inducirajoča sredstva za zdravljenje raka in imunskih bolezni |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
WO2010080864A1 (fr) * | 2009-01-12 | 2010-07-15 | Array Biopharma Inc. | Composés contenant de la pipéridine et leurs utilisations |
WO2011011508A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés doxazépine benzofusionnés en tant quinhibiteurs de la coenzyme-stéaroyle a delta-9 désaturase |
WO2011011506A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
WO2011106273A1 (fr) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques |
WO2011109059A1 (fr) | 2010-03-01 | 2011-09-09 | Gtx, Inc. | Composés destinés au traitement du cancer |
EP2563764B1 (fr) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase |
US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
EA201291236A1 (ru) | 2010-05-13 | 2013-11-29 | Эмджен Инк. | Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10 |
WO2011156246A1 (fr) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Nouveaux inhibiteurs de prolylcarboxypeptidase |
EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US8796258B2 (en) | 2011-02-25 | 2014-08-05 | Merck Sharp & Dohme Corp. | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2012120050A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120051A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation |
WO2012120058A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683704B1 (fr) | 2011-03-08 | 2014-12-17 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
EP2683703B1 (fr) | 2011-03-08 | 2015-05-27 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病二環式化合物 |
EP2970119B1 (fr) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
EP3152200A1 (fr) | 2014-06-06 | 2017-04-12 | Research Triangle Institute | Agonistes du récepteur de l'apeline (apj) et leurs utilisations |
MX2018006979A (es) | 2015-12-09 | 2019-05-16 | Res Triangle Inst | Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos. |
US20200288710A1 (en) | 2016-03-15 | 2020-09-17 | Bayer Cropscience Aktiengesellschaft | Substituted sulphonamides for controlling animal pests |
CN114507217A (zh) | 2016-10-12 | 2022-05-17 | 三角研究所 | 杂环爱帕琳肽受体(apj)激动剂及其用途 |
TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
RU2019117958A (ru) * | 2016-11-18 | 2020-12-18 | Мерк Шарп И Доум Корп. | Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2 |
EP3551176A4 (fr) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
US20220380318A1 (en) | 2019-11-07 | 2022-12-01 | Bayer Aktiengesellschaft | Substituted sulfonyl amides for controlling animal pests |
CA3125847A1 (fr) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Procede de fabrication de composes biologiquement actifs et d'intermediaires connexes |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE140966C (fr) | ||||
US5091405A (en) * | 1987-01-05 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Insecticidal pyrazolines |
DE3808071A1 (de) * | 1988-03-11 | 1989-09-21 | Basf Ag | Verfahren zur herstellung von acylierten imidazolen |
US5164406A (en) * | 1988-06-02 | 1992-11-17 | Bristol-Myers Squibb Co. | Method for enhancing transdermal penetration and compositions useful therein |
DE4015535A1 (de) * | 1990-05-15 | 1991-11-21 | Basf Ag | Verfahren zur herstellung von n-substituierten imidazolen |
AU3592493A (en) | 1992-01-13 | 1993-08-03 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
US5550147A (en) * | 1992-02-05 | 1996-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5565577A (en) * | 1992-09-23 | 1996-10-15 | Smithkline Beecham Corporation | Process for preparing 1-alkyaryl-2-alkyl-5-formylimidazole |
PL180717B1 (pl) * | 1993-11-30 | 2001-03-30 | Searle & Co | N o w e 1 -[4-(aminosulfonylo)fenylo]pirazolilobenzenosulfonamidy do leczenia stanów zapalnych PL PL PL PL PL PL PL |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5519143A (en) * | 1994-09-19 | 1996-05-21 | The Du Pont Merck Pharmaceutical Company | Process for the isolation and purification of an imidazole stereoisomer from a mixture of stereoisomers by selective precipitation |
JP2001506997A (ja) | 1996-12-16 | 2001-05-29 | オントジエン・コーポレイシヨン | ホスホチロシン認識ユニットを有する蛋白質の修飾物質 |
WO1999032454A1 (fr) | 1997-12-22 | 1999-07-01 | Du Pont Pharmaceuticals Company | Heteroaromatiques contenant de l'azote, presentant des groupes p1 a substitution ortho, et utilises en tant qu'inhibiteurs du facteur xa |
ATE306481T1 (de) * | 1999-05-12 | 2005-10-15 | Ortho Mcneil Pharm Inc | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen |
US6492516B1 (en) | 1999-05-14 | 2002-12-10 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
PE20011010A1 (es) | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
US7279477B2 (en) | 2001-01-26 | 2007-10-09 | Chugai Seiyaku Kabushiki Kaisha | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
-
2002
- 2002-09-23 UY UY27450A patent/UY27450A1/es unknown
- 2002-09-23 PE PE2002000931A patent/PE20030547A1/es not_active Application Discontinuation
- 2002-09-23 HN HN2002000266A patent/HN2002000266A/es unknown
- 2002-09-23 AR ARP020103574A patent/AR036608A1/es unknown
- 2002-09-23 GT GT200200188A patent/GT200200188A/es unknown
- 2002-09-24 BR BR0212986-8A patent/BR0212986A/pt not_active IP Right Cessation
- 2002-09-24 WO PCT/US2002/030545 patent/WO2003040107A1/fr not_active Application Discontinuation
- 2002-09-24 NZ NZ531841A patent/NZ531841A/en unknown
- 2002-09-24 EP EP02780365A patent/EP1432691A1/fr not_active Withdrawn
- 2002-09-24 CN CNA028186931A patent/CN1599724A/zh active Pending
- 2002-09-24 CA CA002459745A patent/CA2459745A1/fr not_active Abandoned
- 2002-09-24 MX MXPA04002037A patent/MXPA04002037A/es unknown
- 2002-09-24 JP JP2003542153A patent/JP2005508384A/ja not_active Withdrawn
- 2002-09-24 IL IL16052402A patent/IL160524A0/xx unknown
- 2002-09-24 RU RU2004112770/04A patent/RU2004112770A/ru not_active Application Discontinuation
- 2002-09-24 CN CNA2006100915133A patent/CN1865248A/zh active Pending
- 2002-09-24 HU HU0402376A patent/HUP0402376A2/hu unknown
- 2002-09-24 PL PL02369326A patent/PL369326A1/xx not_active Application Discontinuation
- 2002-09-24 US US10/255,049 patent/US6960601B2/en not_active Expired - Fee Related
- 2002-09-24 KR KR10-2004-7004228A patent/KR20040040472A/ko not_active Application Discontinuation
-
2004
- 2004-03-19 CO CO04026619A patent/CO5560560A2/es not_active Application Discontinuation
- 2004-03-23 NO NO20041216A patent/NO20041216L/no not_active Application Discontinuation
- 2004-03-31 HR HR20040308A patent/HRP20040308A2/xx not_active Application Discontinuation
- 2004-04-21 ZA ZA200403035A patent/ZA200403035B/en unknown
- 2004-04-22 EC EC2004005076A patent/ECSP045076A/es unknown
- 2004-04-23 MA MA27653A patent/MA27684A1/fr unknown
-
2005
- 2005-05-20 US US11/133,751 patent/US20050256167A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003040107A1 (fr) | 2003-05-15 |
CA2459745A1 (fr) | 2003-05-15 |
CN1599724A (zh) | 2005-03-23 |
WO2003040107A8 (fr) | 2004-07-29 |
PL369326A1 (en) | 2005-04-18 |
RU2004112770A (ru) | 2005-10-10 |
HUP0402376A2 (hu) | 2005-02-28 |
GT200200188A (es) | 2003-06-25 |
PE20030547A1 (es) | 2003-08-18 |
BR0212986A (pt) | 2004-08-17 |
MXPA04002037A (es) | 2004-06-07 |
NO20041216L (no) | 2004-05-05 |
CO5560560A2 (es) | 2005-09-30 |
HRP20040308A2 (en) | 2006-08-31 |
UY27450A1 (es) | 2003-04-30 |
US6960601B2 (en) | 2005-11-01 |
ECSP045076A (es) | 2004-05-28 |
ZA200403035B (en) | 2005-04-21 |
AR036608A1 (es) | 2004-09-22 |
US20050256167A1 (en) | 2005-11-17 |
KR20040040472A (ko) | 2004-05-12 |
IL160524A0 (en) | 2004-07-25 |
US20040063691A1 (en) | 2004-04-01 |
HN2002000266A (es) | 2003-11-16 |
JP2005508384A (ja) | 2005-03-31 |
EP1432691A1 (fr) | 2004-06-30 |
NZ531841A (en) | 2005-09-30 |
CN1865248A (zh) | 2006-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27684A1 (fr) | Preparation et utilisation de derives d'imidazole dans le traitement de l'obesite | |
MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
MY129328A (en) | Triamide-substituted heterobicyclic compounds | |
TNSN07248A1 (fr) | Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases | |
YU45403A (sh) | Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida | |
TNSN05104A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
MXPA04002583A (es) | Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1). | |
MXPA03009439A (es) | Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1. | |
MA31766B1 (fr) | Composés organiques | |
MA28007A1 (fr) | Composes organiques | |
WO2004014881A3 (fr) | Nouveaux composes | |
MXPA05013366A (es) | Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c. | |
UA83194C2 (ru) | Производные пиримидина и их применение как модуляторов св2 | |
MA27573A1 (fr) | Sinomenine et derives de sinomenine, synthese et utilisation. | |
AU2002314914A1 (en) | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases | |
TW200504034A (en) | Therapeutic agents | |
PL338352A1 (en) | Derivatives of 1-(n-phenylaminoalkyl)-piperazine substituted at position 2 of its phenyl ring | |
JO2359B1 (en) | Benzathene derivatives as agents for modulation of GABA A receptor | |
GB0102672D0 (en) | Compounds | |
MA27844A1 (fr) | Derives pyrroliques substitues | |
MA29561B1 (fr) | DERIVES DE PYRIDO[2,3-d] PYRIMIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE | |
TW200509933A (en) | Therapeutic agents | |
MY141011A (en) | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | |
MA27592A1 (fr) | Agonistes du recepteur du facteur de liberation 2 de la corticotropine. |